Kukje Pharma Co., Ltd. (KRX:002720)
4,460.00
+110.00 (2.53%)
At close: Dec 17, 2025
Kukje Pharma Revenue
Kukje Pharma had revenue of 45.63B KRW in the quarter ending September 30, 2025, with 15.09% growth. This brings the company's revenue in the last twelve months to 173.80B, up 15.77% year-over-year. In the year 2024, Kukje Pharma had annual revenue of 156.46B with 15.58% growth.
Revenue (ttm)
173.80B
Revenue Growth
+15.77%
P/S Ratio
0.52
Revenue / Employee
700.79M
Employees
248
Market Cap
90.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 156.46B | 21.09B | 15.58% |
| Dec 31, 2023 | 135.37B | 8.79B | 6.94% |
| Dec 31, 2022 | 126.58B | 6.84B | 5.71% |
| Dec 31, 2021 | 119.75B | -10.65B | -8.17% |
| Dec 31, 2020 | 130.39B | 19.27B | 17.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |